Azacitidine tablets are a key maintenance therapy drug for acute myeloid leukemia, and standardized medication and health management are equally important.

Dosage and Administration of Azacitidine Tablets

1. Standard Dose Regimen

(1) The recommended dose is 300 mg once daily, orally.

(2) Each treatment cycle is 28 days, with continuous dosing from Day 1 to Day 14 of each cycle, followed by a 14-day rest period.

(3) Treatment should continue until disease progression or unacceptable toxicity occurs.

2. Pre-dose Preparations

(1) Before the first dose of each cycle, the absolute neutrophil count must be confirmed to be ≥0.5 Gi/L.

(2) If below this value, the cycle should be delayed until blood counts recover before starting.

3. Use of Antiemetics

(1) Antiemetics should be administered 30 minutes before the first dose, and continued for at least the first 2 cycles.

(2) If no nausea or vomiting occurs after 2 cycles, the doctor may consider discontinuing antiemetics.

4. Missed Dose and Vomiting Management

(1) If a dose is missed or not taken at the usual time, take it as soon as possible on the same day, then resume the normal schedule the next day. Do not take two doses in one day.

(2) If vomiting occurs after taking a dose, do not take an additional dose that day; take the next dose as scheduled the next day.

5. Administration Method

(1) Swallow the tablet whole. Do not cut, crush, or chew.

(2) Can be taken with or without food. It is recommended to take at a fixed time each day.

(3) This drug is a hazardous drug. If it comes into contact with skin or mucous membranes, wash immediately.

Precautions for Azacitidine Tablets

1. Substitution Prohibited

(1) Azacitidine tablets should not be interchanged with intravenous or subcutaneous injectable azacitidine.

(2) The indications, doses, and administration regimens for the two forms are completely different.

(3) Incorrect substitution may lead to fatal adverse reactions or treatment failure.

2. Blood Count Monitoring Requirements

(1) Monitor complete blood count every two weeks for the first 2 cycles, then before each subsequent cycle.

(2) Within 2 cycles after any dose reduction, resume monitoring every two weeks.

3. Dose Adjustment Rules

(1) If neutropenia<1 Gi/L with fever or thrombocytopenia <50 Gi/L with bleeding occurs, suspend treatment upon first occurrence. Resume at the original dose after recovery.

(2) If it occurs for two consecutive cycles, reduce the dose to 200 mg after recovery.

(3) If toxicity persists after dose reduction, reduce the number of dosing days per cycle by 7 days. If it occurs again, consider discontinuing treatment.

4. Infection Warning Signs

If symptoms such as fever, chills, fatigue, sore throat, shortness of breath, dizziness, or confusion occur, seek immediate medical attention. These may be early signs of sepsis.

5. Special Populations

(1) Contraindicated during pregnancy; pregnancy testing is required before treatment.

(2) Breastfeeding is not recommended during treatment.

(3) Patients with severe renal impairment require enhanced monitoring for adverse reactions.

Healthy Lifestyle for Patients Taking Azacitidine Tablets

1. Nutritional Support

(1) During nausea and vomiting, choose bland, easily digestible foods.

(2) Eat small, frequent meals and avoid greasy, spicy foods.

(3) During diarrhea, maintain adequate fluid and electrolyte intake; oral rehydration solutions may be used as appropriate.

2. Infection Prevention

(1) Due to the high risk of neutropenia, wash hands frequently, wear a mask, and avoid crowded places.

(2) Maintain oral hygiene and use a soft-bristled toothbrush.

(3) Seek immediate medical attention if body temperature exceeds 38°C (100.4°F); do not wait.

3. Fatigue Management

(1) When feeling tired or weak, rest appropriately and avoid strenuous activities.

(2) Light activities such as walking may be done when energy permits, but avoid overexertion.